Metraipolis › archive › dc_f32bbd01f9f8

Serum metabolomic signatures predict clinical outcomes in advanced non-small cell lung cancer treated with pembrolizumab plus platinum-based chemotherapy — Europe PMC PMID:42233027

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42233027
DOI
10.3389/fimmu.2026.1770764
License (as archived)
solo-consultazione
Archived
2026-11-01T15:45:38.621Z
SHA-256 of the archived text
26a26886a4daa9d4b32dc7d5cd0dafbebf9a1b107879ce88ce0fbbbb8cb99d8c
Stable URL of this page
https://metraipolis.com/documento/dc_f32bbd01f9f8

How to cite

Serum metabolomic signatures predict clinical outcomes in advanced non-small cell lung cancer treated with pembrolizumab plus platinum-based chemotherapy — Europe PMC PMID:42233027 — Europe PMC (en), https://europepmc.org/article/MED/42233027 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f32bbd01f9f8 (Metraipolis archive dc_f32bbd01f9f8, sha256 26a26886a4daa9d4b32dc7d5cd0dafbebf9a1b107879ce88ce0fbbbb8cb99d8c)
BibTeX
@misc{dcf32bbd01f9f8,
  title = {Serum metabolomic signatures predict clinical outcomes in advanced non-small cell lung cancer treated with pembrolizumab plus platinum-based chemotherapy — Europe PMC PMID:42233027},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42233027},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f32bbd01f9f8; sha256 26a26886a4daa9d4b32dc7d5cd0dafbebf9a1b107879ce88ce0fbbbb8cb99d8c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42233027. Agents can read the archived copy with the MCP tool read_document.